Long-term efficacy of adalimumab shows improvement in inflammation control for pediatric non-infectious uveitis, suggesting its use before considering other treatments.
ADA is an effective and safe treatment for pediatric NIU. In patients with inadequate control on biweekly dosing, escalation to weekly ADA improves inflammation control and reduces relapse risk without compromising safety, and should be considered before switching biologic therapy.
No takes yet. Share an insight, caveat, or question.
Esenkaya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: